Here's What Key Metrics Tell Us About ResMed (RMD) Q3 Earnings
Although the revenue and EPS for ResMed (RMD) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
ResMed (RMD) Q3 Earnings and Revenues Surpass Estimates
ResMed (RMD) came out with quarterly earnings of $2.37 per share, beating the Zacks Consensus Estimate of $2.36 per share. This compares to earnings of $2.13 per share a year ago.
ResMed slightly beats quarterly profit estimates on sleep devices demand
Resmed beat Wall Street estimates for third-quarter profit on Wednesday, driven by demand for its sleep apnea devices used to manage the common sleep disorder.
What Analyst Projections for Key Metrics Reveal About ResMed (RMD) Q3 Earnings
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for ResMed (RMD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025.
ResMed (RMD) Reports Next Week: Wall Street Expects Earnings Growth
ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why ResMed (RMD) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Strength Seen in ResMed (RMD): Can Its 3.8% Jump Turn into More Strength?
ResMed (RMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
RMD Stock Benefits From the Launch of NightOwl Across US
Resmed launches NightOwl, an FDA-cleared home sleep apnea test, in the United States to diagnose OSA at home.
Why ResMed (RMD) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Is it Worth Adding ResMed Stock to Your Portfolio Now?
Robust Mask and Device sales bode well for ResMed. Meanwhile, the increasing debt burden adds to the worry.
ResMed Stock Climbs 25.6% in a Year: What's Driving the Rally?
RMD outperforms the industry and the S&P 500 composite due to its success with the cloud-connected AirSense platform.
Here's Why ResMed (RMD) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
